32
IRUS Total
Downloads
  Altmetric

SABINA: an overview of short-acting β2-agonist use in asthma in European countries

File Description SizeFormat 
Janson2020_Article_SABINAAnOverviewOfShort-Acting.pdfPublished version421.25 kBAdobe PDFView/Open
Title: SABINA: an overview of short-acting β2-agonist use in asthma in European countries
Authors: Janson, C
Menzies-Gow, A
Nan, C
Nuevo, J
Papi, A
Quint, J
Quirce, S
Vogelmeier, C
Item Type: Journal Article
Abstract: Introduction Globally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed to describe the current burden of SABA use among European individuals with asthma within the SABA use IN Asthma (SABINA) program. Methods Prescription and/or dispensing data during 2006–2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year. Results More than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55–64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9–32%) and moderate-to-severe (8–31%) asthma in the other European countries. Conclusions The findings of this study from the SABINA program show that SABA overuse (at least three canisters per year) is common across Europe, despite the different healthcare and reimbursement policies of each country.
Issue Date: Mar-2020
Date of Acceptance: 15-Jan-2020
URI: http://hdl.handle.net/10044/1/77002
DOI: 10.1007/s12325-020-01233-0
ISSN: 0741-238X
Publisher: Springer (part of Springer Nature)
Start Page: 1124
End Page: 1135
Journal / Book Title: Advances in Therapy
Volume: 37
Copyright Statement: © 2020 The Author(s). Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Keywords: Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Pharmacology & Pharmacy
Research & Experimental Medicine
Europe
Overreliance
Prescription
Public health
Short-acting beta(2)-agonist
BETA-AGONIST USE
BUDESONIDE-FORMOTEROL
MEDICATION USE
MAINTENANCE
INAPPROPRIATE
PATTERNS
THERAPY
DRUG
Europe
Overreliance
Prescription
Public health
Short-acting β2-agonist
General Clinical Medicine
1115 Pharmacology and Pharmaceutical Sciences
Publication Status: Published
Online Publication Date: 2020-01-24
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine